Bottle Label 300 mg (71610 0328 30)
Pregabalin
Product Images NDC 71610-331
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 22 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 71610-331). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Bottle Label 100 mg (71610 0329 30)
Bottle Label 200 mg (71610 0330 53)
Bottle Label 225 mg (71610 0331 53)
Bottle Label 50 mg (71610 0332 30)
Bottle Label 75 mg (71610 0333 30)
Bottle Label 150 mg (71610 0334 30)
Bottle Label 25 mg (71610 0335 30)
Aphena Pharma Solutions (TN)
Figure 1 (Pregabalin Fig01)
The text seems incomplete and contains non-English characters. Hence, it is not available for evaluation.*
Figure 2 (Pregabalin Fig02)
The given text seems to be a table with headers 'Percent of Patients Improved' and 'Percent Improvement in Pain from Baseline'. The values in the table seem to indicate percentages and dosages of some medication, specifically Pregabalin. The last row seems to indicate a duration or a short description, however, it's not enough to provide a useful description.*
Figure 3 (Pregabalin Fig03)
This appears to be a table or chart showing different medications and the percentage of patients who reported improvement while taking them. The medications listed are Pregatalin 300, Pregabain 160, and Pregabalin 75. Each medication is taken multiple times a day. There is also a line graph that shows the percentage improvement in pain compared to a baseline measurement. However, the text is not entirely legible and some characters are unclear, making it difficult to interpret the data accurately.*
Figure 4 (Pregabalin Fig04)
Figure 5 (Pregabalin Fig05)
This appears to be a table showing the dosages and improvement in pain for three different treatments: Fregabalin 100mg three times a day, Pregataiin 80mg three times a day, and Placebo. The table shows a list of numbers under "Pacent of Patients Improved" and "Pescent Improvement in Pain from Baseline." However, due to the lack of readability and inconsistent formatting, it is difficult to infer any meaningful conclusions from this text.*
Figure 6 (Pregabalin Fig06)
This appears to be a chart or table with headings for two studies labeled E1 and E3, and a reference to study S5. Dosages of a substance labeled in milligrams per day are listed alongside the term "placebo." There is a mention of statistical significance compared to placebo. Based on this limited information, it is not possible to provide a useful description beyond this.*
Figure 7 (Pregabalin Fig07)
Figure 9 (Pregabalin Fig08)
The text represents a chart or graph showing the percentage of patient improvement in pain from baseline for different doses of Pregabalin compared to a placebo. The chart shows the percentage improvement for a Pregabalin daily dose of 300mg and 450mg compared to a placebo. The X-axis of the chart shows values ranging from 20 to 280, and the Y-axis is labeled "Percent Improvement in Pain from Baseline."*
Figure 10 (Pregabalin Fig09)
The text appears to be a graph showing the estimated percentage of subjects without LTR (unknown acronym) over time, possibly related to a clinical trial. The graph shows two lines labeled "Progabain" and "Placebo." The x-axis is labeled in days.*
Figure 11 (Pregabalin Fig10)
Figure 12 (Pregabalin Fig11)
The text provides a graph showing the percentage of subjects who improved from baseline to week 16 BOCF for Pregabalin and Placebo. The graph displays data points at 100, 210, 220, 230, 240, 250, 260, 270 percent improvement and lists Pregabalin and Placebo as the treatments being compared.*
Cockcroft And Gault Equation (Pregabalin Formula)
This text appears to be a medical formula for calculating the creatinine clearance rate (CLCT) in patients. The CLCT measures how effectively the kidneys are working to filter waste and excess fluids from the blood. The formula involves subtracting the patient's age from 140, multiplying it by their weight in kilograms, and then multiplying by 0.85 if the patient is female. The result is then multiplied by their serum creatinine level in milligrams per deciliter and divided by 72. This provides an estimated measure of how many milliliters of blood the kidneys are able to clear of creatinine per minute.*
Chemical Structure (Pregabalin Str)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
